Lucia Nogová

4.2k total citations
86 papers, 1.5k citations indexed

About

Lucia Nogová is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Lucia Nogová has authored 86 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in Lucia Nogová's work include Lung Cancer Treatments and Mutations (48 papers), Lymphoma Diagnosis and Treatment (21 papers) and Cancer Genomics and Diagnostics (15 papers). Lucia Nogová is often cited by papers focused on Lung Cancer Treatments and Mutations (48 papers), Lymphoma Diagnosis and Treatment (21 papers) and Cancer Genomics and Diagnostics (15 papers). Lucia Nogová collaborates with scholars based in Germany, United States and Switzerland. Lucia Nogová's co-authors include Volker Diehl, Andreas Josting, Andreas Engert, Michal Sieniawski, Thorsten Reineke, Andreas Engert, Matthias Scheffler, Jürgen Wolf, Thomas Zander and Thomas Rüdiger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Lucia Nogová

77 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lucia Nogová Germany	24	698	683	642	337	314	86	1.5k
B.Y. Yeap United States	20	595 0.9×	805 1.2×	1.0k 1.6×	227 0.7×	563 1.8×	65	2.0k
Tara Baetz Canada	20	514 0.7×	904 1.3×	391 0.6×	155 0.5×	317 1.0×	71	1.5k
Eliza A. Hawkes Australia	20	1.0k 1.5×	847 1.2×	230 0.4×	364 1.1×	198 0.6×	133	1.6k
Xiaonan Hong China	20	930 1.3×	1.0k 1.5×	416 0.6×	174 0.5×	248 0.8×	71	1.7k
Patrizia Pregno Italy	18	690 1.0×	710 1.0×	248 0.4×	289 0.9×	607 1.9×	74	1.8k
Annalisa Chiappella Italy	23	1.3k 1.9×	782 1.1×	187 0.3×	506 1.5×	254 0.8×	111	1.7k
Liliana Devizzi Italy	22	1.5k 2.2×	960 1.4×	376 0.6×	456 1.4×	124 0.4×	59	1.9k
Emmanuelle Fourme France	14	426 0.6×	311 0.5×	216 0.3×	299 0.9×	287 0.9×	30	1.2k
Simone Ferrero Italy	18	583 0.8×	462 0.7×	176 0.3×	152 0.5×	347 1.1×	82	1.3k
Graham W. Slack Canada	24	1.7k 2.4×	1.1k 1.6×	278 0.4×	571 1.7×	224 0.7×	97	2.2k

Countries citing papers authored by Lucia Nogová

Since Specialization

Citations

This map shows the geographic impact of Lucia Nogová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucia Nogová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucia Nogová more than expected).

Fields of papers citing papers by Lucia Nogová

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucia Nogová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucia Nogová. The network helps show where Lucia Nogová may publish in the future.

Co-authorship network of co-authors of Lucia Nogová

This figure shows the co-authorship network connecting the top 25 collaborators of Lucia Nogová. A scholar is included among the top collaborators of Lucia Nogová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucia Nogová. Lucia Nogová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riedel, Richard, Lucia Nogová, Sebastian Michels, et al.. (2025). MET-Driven Resistance to Sotorasib in KRAS G12C–Mutant NSCLC and Response to Combined KRAS and MET Inhibition. JTO Clinical and Research Reports. 7(3). 100925–100925.

Satoh, Taroh, Philippe Barthélémy, Lucia Nogová, et al.. (2025). Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications. European Journal of Cancer. 218. 115262–115262. 5 indexed citations

Nogová, Lucia, Florian Malchers, Axel M. Hillmer, et al.. (2023). 1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Annals of Oncology. 34. S767–S767. 2 indexed citations

Fassunke, Jana, Michael Püsken, Elke Binot, et al.. (2023). Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report. JCO Precision Oncology. 7(7). e2200467–e2200467. 2 indexed citations

George, Julie, Andreas H. Scheel, Hans Anton Schloesser, et al.. (2022). 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort. Annals of Oncology. 33. S1025–S1025. 1 indexed citations

Scheffler, Matthias, Sebastian Michels, & Lucia Nogová. (2022). Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. Die Innere Medizin. 63(7). 700–708.

Riedel, Richard, Sebastian Michels, Carina Heydt, et al.. (2019). Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma. Lung Cancer. 133. 20–22. 2 indexed citations

Riedel, Richard, Anna Kron, Sebastian Michels, et al.. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Annals of Oncology. 28. v474–v474.

Kron, Anna, Richard Riedel, Sebastian Michels, et al.. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Annals of Oncology. 28. v461–v462. 6 indexed citations

10.

Koleczko, Sophia, Matthias Scheffler, Michaela A. Ihle, et al.. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC – a comparison of NGM and TCGA LUSC data. Annals of Oncology. 27. vi420–vi420. 1 indexed citations

11.

Suleiman, Ahmed A., Sebastian Frechen, Matthias Scheffler, et al.. (2015). A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. The AAPS Journal. 17(6). 1483–1491. 9 indexed citations

12.

Nogová, Lucia, Matthias Scheffler, Sebastian Michels, et al.. (2014). Try - a Phase Ii Study to Evaluate Safety and Efficacy of Combined Trastuzumab and the Hsp90 Inhibitor Auy922 in Advanced Non-Small-Cell Lung Cancer (Nsclc) with Her2 Overexpression or Amplification or Mutation. Annals of Oncology. 25. iv433–iv433. 1 indexed citations

13.

Scheffler, Matthias, Lucia Nogová, Masyar Gardizi, et al.. (2012). BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.. Journal of Clinical Oncology. 30(15_suppl). TPS3115–TPS3115. 1 indexed citations

14.

Kahraman, Deniz, Matthias Scheffler, Thomas Zander, et al.. (2011). Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using ¹⁸F-FDG and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET. Journal of Nuclear Medicine. 52(12). 1871–1877. 60 indexed citations

15.

Nogová, Lucia, Ronald Boellaard, Carsten Kobe, et al.. (2009). Downregulation of ¹⁸F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus. Journal of Nuclear Medicine. 50(11). 1815–1819. 24 indexed citations

16.

Soria, Jean‐Charles, Frances A. Shepherd, Jean‐Yves Douillard, et al.. (2009). Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology. 20(10). 1674–1681. 139 indexed citations

17.

Sieniawski, Michal, Thorsten Reineke, Andreas Josting, et al.. (2008). Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology. 19(10). 1795–1801. 73 indexed citations

18.

Nogová, Lucia, Thorsten Reineke, Corinne Brillant, et al.. (2007). Lymphocyte-Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. Journal of Clinical Oncology. 26(3). 434–439. 134 indexed citations

19.

Bredenfeld, Henning, Jeremy Franklin, Lucia Nogová, et al.. (2004). Severe Pulmonary Toxicity in Patients With Advanced-Stage Hodgkin's Disease Treated With a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen Is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology. 22(12). 2424–2429. 43 indexed citations

20.

Diehl, Volker, Corinne Brillant, Andreas Engert, et al.. (2004). Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG.. Blood. 104(11). 1307–1307. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact